CG Oncology, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CG Oncology, Inc. (CGON) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- CG Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $1.50M.
- CG Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $791.00K, a 7.92% decline year-over-year.
- CG Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- CG Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- CG Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $859.00K.
- CG Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- CG Oncology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $221.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.50M 10-Q · filed 2026-08-06 | $2.29M 10-Q · filed 2026-08-06 | $2.29M derived: sum of 3 quarters · filed 2026-08-06 | $2.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $791.00K 10-Q · filed 2026-05-08 | $791.00K derived: sum of 2 quarters · filed 2026-05-08 | $791.00K derived: sum of 3 quarters · filed 2026-05-08 | $791.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $859.00K 10-K · filed 2026-02-27 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $859.00K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $859.00K 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $859.00K 10-Q · filed 2026-05-08 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-27 | |||
| 2023-12-31 | $221.00K 10-K · filed 2026-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |